Trial Profile
A Study Investigating Medication Adherence and Persistence in Patients Taking Deferasirox Dispersible Tablets (DFX-DT) and Film-Coated Tablets (DFX-FCT) and in Patients who switched from DFX-DT to DFX-FCT (Texas Medicaid Patients)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2017
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- 29 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.